Ph.D. Ronald A. Pepin - 15 Dec 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SR. VP & CBO
Signature
/s/ Sam Martin, attorney-in-fact for Ronald A. Pepin, Ph.D.
Issuer symbol
CLDX
Transactions as of
15 Dec 2025
Net transactions value
+$105,714
Form type
4
Filing time
17 Dec 2025, 16:06:34 UTC
Previous filing
09 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PEPIN RONALD SR. VP & CBO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON /s/ Sam Martin, attorney-in-fact for Ronald A. Pepin, Ph.D. 17 Dec 2025 0001214504

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $75,134 +8,333 +1091% $9.02 9,097 15 Dec 2025 Direct F1, F2
transaction CLDX Common Stock Options Exercise $30,580 +11,000 +121% $2.78 20,097 15 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -8,333 -62% $0.000000 5,000 15 Dec 2025 Common Stock 8,333 $9.02 Direct F1, F3
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -11,000 -100% $0.000000 0 15 Dec 2025 Common Stock 11,000 $2.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F2 Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F3 As of June 13, 2022, the option is fully vested.
F4 As of June 19, 2023, the option is fully vested.